Trademark: 97232428
Word
MEDILINK
Status
Registered
Status Code
700
Status Date
Tuesday, August 20, 2024
Serial Number
97232428
Registration Number
7482728
Registration Date
Tuesday, August 20, 2024
Mark Type
5
Filing Date
Friday, January 21, 2022
Published for Opposition
Tuesday, December 6, 2022

Trademark Owner History

Classifications
5 Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposes, namely, for treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignant, inflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydration, nutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations, namely, elixirs for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseases, for the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemia, cancer, cardiovascular system diseases, central nervous system diseases, peripheral nervous system diseases, circulatory system diseases, digestive system diseases, autoimmune diseases, bacteria-based diseases and infectious diseases; Tumor suppressing agents
The mark consists of the stylized wording "MEDILINK".
MEDI LINK
Color is not claimed as a feature of the mark.
The wording "MEDILINK" has no meaning in a foreign language.

Trademark Events
Jan 26, 2022
New Application Office Supplied Data Entered
Jan 25, 2022
New Application Entered
Oct 28, 2022
Assigned To Examiner
Nov 1, 2022
Approved For Pub - Principal Register
Nov 16, 2022
Notification Of Notice Of Publication E-Mailed
Dec 6, 2022
Published For Opposition
Dec 6, 2022
Official Gazette Publication Confirmation E-Mailed
Jan 31, 2023
Noa E-Mailed - Sou Required From Applicant
Jul 18, 2023
Use Amendment Filed
Aug 3, 2023
Case Assigned To Intent To Use Paralegal
Aug 3, 2023
Statement Of Use Processing Complete
Aug 8, 2023
Su - Non-Final Action - Written
Jul 18, 2023
Teas Statement Of Use Received
Aug 8, 2023
Non-Final Action E-Mailed
Aug 8, 2023
Notification Of Non-Final Action E-Mailed
Nov 6, 2023
Application Extension Granted/Receipt Provided
Jul 2, 2024
Correspondence Received In Law Office
Jul 2, 2024
Teas/Email Correspondence Entered
Jul 15, 2024
Allowed Principal Register - Sou Accepted
Jul 15, 2024
Notice Of Acceptance Of Statement Of Use E-Mailed
Aug 20, 2024
Registered-Principal Register
Aug 20, 2024
Notice Of Registration Confirmation Emailed
Jul 2, 2024
Assigned To Lie
Nov 6, 2023
Application Extension To Response Period - Received
Jan 8, 2024
Teas Response To Office Action Received

Trademark Alertz updated from USPTO on 2030-01-24